🇺🇸 FDA

Company profile · Sponsor

Autolus

Autolus GmbH

AUTL · NYSE pharma LONDON, X0, EU
Pipeline
16
Drugs
1
Patents
8

Quick answer

Autolus (AUTL) is a pharma company. headquartered in LONDON, X0, EU. listed on NYSE. NovaPharmaNews links 16 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker AUTL
Exchange NYSE
Company type pharma
Headquarters LONDON, X0, EU
SEC CIK 0001730463

Pipeline (16)

Search pipeline →

  1. AUTO CAR T cell therapy

    Autolus

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

    phase 2 mab active

    1 trial

  2. AUTO1

    Autolus

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials

  3. AUTO1, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludara 50 mg powder for solution for injection or infusion

    Autolus

    Systemic Lupus Erythematosus with Active Lupus Nephritis

    phase 2 small molecule active

    1 trial

  4. AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion

    Autolus

    Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.

    phase 2 small molecule active

    1 trial

  5. AUTO2

    Autolus

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  6. AUTO3

    Autolus

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 mab terminated

    1 trial

  7. AUTO3 (CD19/22 CAR T cells

    Autolus

    B Acute Lymphoblastic Leukemia

    phase 2 mab completed

    1 trial

  8. AUTO4

    Autolus

    T Cell Non-Hodgkin Lymphoma

    phase 2 mab terminated

    1 trial

  9. Genoxal 200 mg polvo para solución inyectable y para perfusión, Fludarabina Teva 25 mg/ml concentrado para solución para perfusión o inyección EFG, AUTO1, Paracetamol MABO 500 mg comprimidos

    Autolus

    Relapsed or refractory B cell acute lymphoblastic leukaemia

    phase 2 small molecule active

    1 trial

  10. Obecabtagene Autoleucel

    Autolus

    Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  11. Obecabtagene autoleucel

    Autolus

    Acute Lymphocytic Leukemia (ALL)

    phase 2 small molecule active

    1 trial

  12. Obecabtagene autoleucel

    Autolus

    Lupus Nephritis

    phase 2 mab active

    1 trial

  13. A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

    Autolus

    Refractory Progressive Multiple Sclerosis

    phase 1 other active

    1 trial

  14. A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients with Severe, Refractory Systemic Lupus Erythematosus

    Autolus

    Severe, Refractory Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  15. Obecabtagene autoleucel (obe-cel)

    Autolus

    Progressive Multiple Sclerosis

    phase 1 mab active

    1 trial

  16. Obecabtagene autoleucel (obe-cel)

    Autolus

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

Drugs (1)

Search drugs →

  1. obecabtagene autoleucel

    AUCATZYL

    L01XL

Patents (8)

Search patents →

  1. US 12398194

    Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12325733

    Binding domain

    Expires Mon Jun 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12304942

    Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising a chimeric TNF receptor

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12269860

    Compositions and methods comprising engineered chimeric antigen receptor and modulator of CAR

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12241068

    CD79-specific chimeric antigen receptor

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12234295

    Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12187769

    Cell

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12049510

    Chimeric antigen receptor

    Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Autolus?

Autolus (AUTL) is a pharma company. headquartered in LONDON, X0, EU. listed on NYSE. NovaPharmaNews links 16 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Autolus sponsor?

We track 16 ClinicalTrials.gov-linked programs for Autolus, including AUTO CAR T cell therapy and 15 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Autolus company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.